Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, LaBonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Zhang W, et al. Among authors: pohl a. Ann Oncol. 2011 Jan;22(1):104-109. doi: 10.1093/annonc/mdq315. Epub 2010 Jul 5. Ann Oncol. 2011. PMID: 20603437 Free PMC article. Clinical Trial.
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. Pohl A, et al. Pharmacogenomics J. 2013 Apr;13(2):173-80. doi: 10.1038/tpj.2011.61. Epub 2012 Jan 10. Pharmacogenomics J. 2013. PMID: 22231565 Free PMC article.
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ. Hu-Lieskovan S, et al. Among authors: pohl a. Clin Cancer Res. 2011 Aug 1;17(15):5161-9. doi: 10.1158/1078-0432.CCR-10-2666. Epub 2011 Jun 14. Clin Cancer Res. 2011. PMID: 21673069 Free PMC article.
Primary Open Versus Closed Implantation Strategy for Totally Implantable Venous Access Ports: The Multicentre Randomized Controlled PORTAS-3 Trial (DRKS 00004900).
Hüttner FJ, Bruckner T, Hackbusch M, Weitz J, Bork U, Kotschenreuther P, Heupel O, Kümmel S, Schlitt HJ, Mattulat M, Pintér L, Seiler CM, Gutt CN, Nottberg HS, Pohl A, Ghanem F, Meyer T, Imdahl A, Neudecker J, Müller VA, Gehrig T, Reineke M, von Frankenberg M, Schumacher G, Hennes R, Mihaljevic AL, Rossion I, Klose C, Kieser M, Büchler MW, Diener MK, Knebel P. Hüttner FJ, et al. Among authors: pohl a. Ann Surg. 2020 Dec;272(6):950-960. doi: 10.1097/SLA.0000000000003705. Ann Surg. 2020. PMID: 31800490 Clinical Trial.
Roadmap towards safe and sustainable advanced and innovative materials. (Outlook for 2024-2030).
Cassee FR, Bleeker EAJ, Durand C, Exner T, Falk A, Friedrichs S, Heunisch E, Himly M, Hofer S, Hofstätter N, Hristozov D, Nymark P, Pohl A, Soeteman-Hernández LG, Suarez-Merino B, Valsami-Jones E, Groenewold M. Cassee FR, et al. Among authors: pohl a. Comput Struct Biotechnol J. 2024 Jun 2;25:105-126. doi: 10.1016/j.csbj.2024.05.018. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38974014 Free PMC article. Review.
304 results